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Abstract
Background International guidelines recommend ninteda-
nib (OFEV) as an option for the treatment of idiopathic
pulmonary fibrosis (IPF).
Objective The objective of this study was to assess the cost
effectiveness of nintedanib versus pirfenidone, N-acetyl-
cysteine and best supportive care (BSC) for the treatment
of IPF from a UK payer’s perspective.
Methods A Markov model was designed to capture the
changes in the condition of adults with IPF. Efficacy out-
comes included mortality, lung function decline and acute
exacerbations. Treatment safety (serious adverse events)
and tolerability (overall discontinuation) were also con-
sidered. The baseline risk of these events was derived from
patient-level data from the placebo arms of nintedanib
clinical trials (TOMORROW, INPULSIS-1, INPULSIS-2).
A network meta-analysis (NMA) was conducted to esti-
mate the relative effectiveness of the comparator treat-
ments. Quality of life and healthcare resource use data
from the clinical trials were also incorporated in the eco-
nomic model.
Results Nintedanib showed statistically significant differ-
ences against placebo on acute exacerbation events
avoided and lung function decline. In the cost-effective-
ness analysis, the results were split between two treat-
ments with relative low costs and modest effectiveness
(BSC and N-acetylcysteine) and two that showed
improved effectiveness (lung function) and higher costs
(nintedanib and pirfenidone). All comparators were
assumed to have similar projected survival and the dif-
ference in quality-adjusted life-years (QALYs) was driven
by the acute exacerbations and lung function estimates. In
the base-case deterministic pairwise comparison with
pirfenidone, nintedanib was found to have fewer acute
exacerbations and resulted in less costs and more QALYs
gained.
Conclusions Compared with BSC (placebo), nintedanib
and pirfenidone were the only treatments to show statistical
significance in the efficacy parameters. We found sub-
stantial uncertainty in the overall cost-effectiveness results
between nintedanib and pirfenidone. N-Acetylcysteine was
largely similar to BSC but with a worse survival profile.
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NCT01335464 and NCT01335477
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Key Points for Decision Makers
A network meta-analysis showed that nintedanib was
significantly better than placebo in acute
exacerbations and lung function decline related to
idiopathic pulmonary fibrosis. Pirfenidone reached
statistical significance for lung function decline.
There was uncertainty about the overall survival
benefits of active treatments compared with placebo.
The analysis of the trial data showed a logical trend
in the association of resource use estimates and lung
function as well as between EQ-5D and lung
function, i.e. increasing resource use (mainly
hospitalisation) and decreasing EQ-5D scores with
lung function decline.
In the base-case analysis, nintedanib and pirfenidone
were largely equivalent in estimated costs and
benefits; the results were driven mainly by the risk of
acute exacerbations.
N-Acetylcysteine was dominated by the reference
strategy (best supportive care) due to a worse
survival profile.
1 Introduction
Idiopathic pulmonary fibrosis (IPF) is a rare, chronic,
progressive and fatal lung disease of unknown origin
characterised by irreversible lung function decline [1]. The
prevalence of IPF in the UK is estimated to be between 15
and 25 cases per 100,000 people [2].
Treatment of IPF focuses on managing symptoms and
slowing disease progression. The majority of patients
receive best supportive care (BSC), which consists of
smoking cessation, oxygen therapy, pulmonary rehabilita-
tion, opiates, anti-reflux therapy, low-dose corticosteroids
and palliative care [1]. A minority of patients are eligible
for lung transplant [3]. Few pharmacological treatments are
available to treat IPF. Triple therapy with prednisone,
azathioprine and N-acetylcysteine was once widely used,
but has been shown to result in an increased risk of death
and serious adverse events (AEs) [4]. Although N-acetyl-
cysteine monotherapy may be used, it has shown little
benefit compared with placebo [5]. In 2011, the European
Medicines Agency (EMA) approved pirfenidone for the
treatment of IPF. In 2015, the EMA approved nintedanib
(OFEV; Boehringer Ingelheim, Ingelheim, Germany) for
this indication.
International guidelines recommend nintedanib and
pirfenidone as treatments for IPF, thus providing physi-
cians and their patients with genuinely effective therapeutic
options [6]. Both nintedanib and pirfenidone are approved
for reimbursement by the National Institute for Health and
Care Excellence (NICE) [7, 8] and the Scottish Medicines
Consortium (SMC) [9, 10] under confidential patient
access scheme (PAS) discounts and restricted market
access conditions. The objective of this study was to assess
the cost effectiveness of nintedanib for the treatment of IPF
against established treatments in the UK. We provide an
overview of the analysis and model that was submitted to
NICE and the SMC in 2015 and discuss its strengths and
limitations.
2 Methods
A Markov model was designed to capture the changes in
the condition of adults with IPF. To determine the structure
of the model, we reviewed a cost-effectiveness evaluation
focused on the non-pharmacological treatment of IPF that
was available at the time of the analysis [1], and identified
several outcomes that described the absolute state of
patient condition: overall survival (OS), acute exacerba-
tions and disease progression, defined as lung function
decline. Several methods were explored using patient-level
clinical trial data [11, 12] to examine the interdependencies
of the three outcomes.
Clinical outcomes that could impact disease progression
and clinical deterioration were considered for the definition
of model health states. A literature review identified studies
that assessed a single parameter [13–20] and those using
risk scoring systems with multiple parameters [21, 22].
Forced vital capacity (FVC) was the most commonly
reported measure in the literature and in clinical trials
[7, 8, 10, 17], and was selected as the main factor deter-
mining disease progression. FVC percent predicted
(FVC %pred) was reported across the majority of pub-
lished clinical trials and was therefore preferred to raw (i.e.
absolute) FVC values. FVC %pred is adjusted for the age,
sex and height of the patient, thus removing some of the
heterogeneity of the health-state members; it also adheres
to Markov model conventions. Our choice for the optimal
FVC %pred range was informed by several exploratory
analyses on the impact to the model results during the
conceptualisation phase. After consultation with clinical
experts (GJ and TM) and consideration of the evidence
from the INPULSIS trials [12] and the literature [23, 24], it
was decided that a 10-point categorisation of FVC %pred
was the most clinically appropriate and methodologically
feasible value for use in this analysis.
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A number of key health states were used to represent IPF
disease progression and possible transitions between them
(Fig. 1). The cohort entered the model with different levels
of FVC %pred and without a history of acute exacerbation
(see Electronic Supplementary Material Online Resource
1). Patients who progressed to a lower FVC %pred could
not regress back to health states with better lung function.
History of an acute exacerbation was assumed to influence
the health status of patients. We assumed that death could
occur (a) at any point in the model (and from any health
state); or (b) at the point that patients drop below a level of
FVC %pred of 40%, which was assumed to be an unsus-
tainable level of lung function [1].
2.1 Treatment Efficacy
The model used evidence from three randomised controlled
trials (RCTs) for nintedanib: the phase II TOMORROW
(To Improve Pulmonary Fibrosis with BIBF 1120) trial and
two phase III INPULSIS trials (INPULSIS-1 and INPUL-
SIS-2) [11, 12]. Data for pirfenidone and N-acetylcysteine
were either extracted from the main pirfenidone and N-
acetylcysteine publications [25, 26] or were obtained from
a network meta-analysis (NMA) comparing the active
comparator treatments.
In the absence of head-to-head data for all comparators,
an NMA was developed based on evidence from nine
studies [11, 12, 25–31]. Key efficacy parameters, such as
OS, acute exacerbations and lung function decline, were
assessed. Other efficacy outcomes analysed in the NMA,
but not included in the cost-effectiveness model, were the
6-min walk test and progression-free survival. A more
detailed description of the NMA methodology and results
is available in Online Resource 2.
The model captured three types of transition related to
treatment efficacy: OS, acute exacerbations and lung
function decline (see Online Resource 3). To define the
baseline mortality risk, a survival analysis was conducted
on patient-level data from the TOMORROW and
INPULSIS trials [11, 12]. Five regression models were
assessed for goodness of fit: exponential, Gompertz, log-
logistic, log-normal and Weibull. The log-logistic, Weibull
and Gompertz parametric models returned the lowest
Akaike Information Criterion values and were compared
with data from observational studies in patients with IPF
(Fig. 2) [5, 19]. The log-logistic model showed the best fit
with these and was therefore used for the base-case anal-
ysis, while the alternatives were used in sensitivity analy-
ses. It was assumed that following an acute exacerbation,
patients would experience an increased risk of death, which
was implemented as a hazard ratio of 1.40 per cycle [5].
Data on acute exacerbations from the placebo arms of the
INPULSIS trials were used to estimate the baseline risk.
Time to first acute exacerbation was recorded in two ways
in the INPULSIS trials: (a) based on investigator-reported
events; and (b) based on events adjudicated as confirmed or
suspected acute exacerbations by a blinded adjudication
committee [12]. The exponential model was judged to be
the best fit; the 3-month acute exacerbation risks were 1.97
and 1.47% for investigator-reported and adjudicated-
Fig. 1 Model structure
Fig. 2 Comparison of overall survival of the model best supportive
care arm with observational data [5, 19]. BSC best supportive care
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confirmed/suspected exacerbations, respectively. The eco-
nomic model used the investigator-reported estimate in the
base-case analysis. The same risk value was assumed for
recurrent events due to a lack of other evidence.
The interdependency between exacerbation and the
baseline lung function risk was explored in the economic
model using data from the INPULSIS trials [12]. A logistic
model was used, capturing the current FVC %pred state for
patients’ acute exacerbation status (i.e. progression before
and after an exacerbation) (Model b). The exacerbation
covariate was not statistically significant (p = 0.445) and
Model a was used in the base-case analysis.
Model a : LFt1 ¼ 4:180þ 0:016 FVC % predt0
Model b : LFt1
¼ 4:180þ 0:016 FVC % predt0 þ 0:814
 Exa
where LFt1 is the lung function at the end of the interval
(time t1), FVC %predt0 is the value of the FVC %pred at
the start of the interval (time t0) and Exa is the exacerbation
covariate (whether an exacerbation occurred during the
previous cycle).
The relative effectiveness of nintedanib, pirfenidone and
N-acetylcysteine for OS, lung function decline and acute
exacerbations against the baseline risk was calculated using
odds ratios (ORs) obtained in the NMA (Table 1).
2.2 Treatment Safety and Tolerability
The analysis assumed that patients were at risk of AEs for
as long as they received treatment. To ensure comparability
with the comparator evidence and homogeneity of the AEs,
a number of criteria were assessed when considering AEs
for inclusion in the model (see Online Resource 4 for
details on the selection criteria). Two serious AEs were
common across any two comparators (serious cardiac
events and serious gastrointestinal events), and were
included in the NMA. Treatment tolerability was consid-
ered using data on discontinuation due to AEs and overall
discontinuation, and was also included in the NMA (Online
Resource 2).
The baseline risk for these events was calculated from
the placebo arms of the INPULSIS trials [12] (Table 2).
ORs for nintedanib, pirfenidone and N-acetylcysteine
Table 1 Results of the network
meta-analysis
Outcome Comparison OR median value 95% CI
Overall survival Nintedanib vs. placebo 0.70 0.45–1.09
Pirfenidone vs. placebo 0.69 0.45–1.04
N-acetylcysteine vs. placebo 2.13 0.53–10.92
Acute exacerbationsa Nintedanib vs. placebo 0.56 0.35–0.89
Pirfenidone vs. placebo 1.10 0.43–2.85
N-acetylcysteine vs. placebo 0.54 0.13–1.90
Lung function decline Nintedanib vs. placebo 0.54 0.42–0.69
Pirfenidone vs. placebo 0.55 0.41–0.72
N-acetylcysteine vs. placebo 1.02 0.59–1.76
Serious cardiac events Nintedanib vs. placebo 0.76 0.45–1.27
Pirfenidone vs. placebo 1.26 0.65–2.49
N-acetylcysteine vs. placebo 5.40 1.27–41.00
Serious gastrointestinal events Nintedanib vs. placebo 2.35 1.05–5.88
Pirfenidone vs. placebo 0.60 0.23–1.45
N-acetylcysteine vs. placebo 0.03 0.00–0.46
Overall discontinuation Nintedanib vs. placebo 1.42 1.08–1.87
Pirfenidone vs. placebo 1.34 1.34–1.73
N-acetylcysteine vs. placebo 1.21 0.68–2.15
CI confidence interval, NMA network meta-analysis, OR odds ratio
a The NMA was performed on investigator-reported acute exacerbations
Table 2 Incidence and risk of
serious adverse events in the
placebo arm of the INPULSIS
trials (n = 423) [12]
SAE Serious cardiac events Serious gastrointestinal events
Number of patients experiencing the event 23 7
Risk of SAE per cycle (%) 1.39 0.42
SAE serious adverse event
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versus placebo were obtained from the NMA (Table 1).
The list of included AEs was reviewed by a clinical expert
and was supplemented with other clinically important AEs
identified for nintedanib and pirfenidone (Table 3).
Regarding discontinuation, both nintedanib and pir-
fenidone are novel treatments with limited real-world
evidence. We analysed data from the INPULSIS trials [12]
to determine a baseline risk (placebo arm: 5.5% per cycle)
and used the NMA to reflect the relative tolerability of the
active comparators (Table 1). We assumed that BSC is the
minimum care patients would receive and therefore there
would be no discontinuation.
2.3 Health-Related Quality of Life Inputs
An analysis of patient-level data from the INPULSIS trials
[12] provided EQ-5D evidence on categories by
FVC %pred status (Table 4). This served as the baseline
utility dependent on the patient condition. A separate
analysis of data from the INPULSIS trials provided esti-
mates for utility decrements for acute exacerbations and
serious gastrointestinal events [12]. Disutility estimates for
serious cardiac events, skin disorders and gastrointestinal
perforation were obtained from a retrospective analysis of a
UK database [32].
2.4 Cost Inputs
The cost inputs considered in the cost-effectiveness anal-
ysis were drug acquisition, treatment-related AEs, moni-
toring tests (liver panel tests), background follow-up,
oxygen use, acute exacerbation costs and end-of-life (EoL)
palliative care costs. The cost inputs were synthesised
using unit cost information from the UK [33–35].
The list price of nintedanib was assumed at parity with
the published list price of pirfenidone in the UK, i.e. £71.7
per day [34] when pirfenidone was administered at a dose
of 2403 mg/day [36]. The assumed nintedanib dose was
300 mg/day (150 mg twice daily) [12], with no dose
reduction allowed. Due to the likely overlap of background
follow-up and BSC, it was assumed that a similar level of
pharmacological costs would apply to active treatments
and control (placebo arm of the INPULSIS trials [12]). We
assumed the N-acetylcysteine cost per mg was £0.001125
[34] and the recommended dose was 600 mg three times
daily. The model allowed dose escalation for the N-
acetylcysteine arm up to 3143.52 mg/day from week 39
onwards, as described in the PANTHER-IPF (Prednisone,
Azathioprine, and N-acetylcysteine: a study THat Evalu-
ates Response in Idiopathic Pulmonary Fibrosis) trial [25].
AE-related costs were obtained from the National Health
Service (NHS) reference costs for 2012/2013 [35].
The cost of background follow-up and acute exacerba-
tions were compiled using patient-level data from the
INPULSIS trials, which recorded resource use related to
hospitalisation, emergency room visits and medical pro-
cedures, and UK unit costs (Table 4). A detailed descrip-
tion of the background follow-up and acute exacerbation
cost calculation is available in Online Resource 5.
Some patients on nintedanib and pirfenidone had ele-
vated hepatic enzyme values [36, 37]. Liver panel tests
were assumed to be routinely performed on patients
receiving nintedanib and pirfenidone. The cost of a liver
panel test was estimated at £3.01 [35], and was assumed to
be incurred by all patients on active treatment at a quarterly
frequency (i.e. every cycle). The model assumed that
patients who dropped below a level of FVC %pred of 80%
would require oxygen supplementation [1], assumed to cost
£418 per cycle [38] (value inflated from 2010/2011 to
2012/2013 using the most recent inflation indices at the
time of the analysis [33]). The model assumed that patients
receive EoL palliative care in the last year of life, costing
£3921 per cycle [39] (value inflated from 2007/2018 to
2012/2013 [33]). All model inputs and assumptions were
validated by clinicians (co-author T.M. Maher and advisor
G. Jenkins).
2.5 Analysis
The cost-effectiveness of nintedanib compared with pir-
fenidone, BSC and N-acetylcysteine was estimated with the
incremental cost-effectiveness ratio (ICER), which
Table 3 Incidence and risk of clinically important adverse events for the nintedanib [12, 53] and pirfenidone [26] arms of the model
Nintedanib arm Pirfenidone arm
Gastrointestinal perforation Photosensitivity reaction Rash
Placebo Nintedanib Placebo Pirfenidone Placebo Pirfenidone
Total number of patients 508 723 347 345 347 345
Number of patients experiencing the event 0 2 6 42 40 111
Risk of SAE per cycle (%) 0 0.08 0.32 2.32 2.19 6.79
SAE serious adverse event
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Table 4 Health-related quality of life and cost inputs for the model
Mean value (SD) Source
Baseline utilities by FVC %pred status
C110% Assumed same value as 90–99.9% N/A
100–109.9% Assumed same value as 90–99.9% N/A
90–99.9% 0.8380 (0.1782) [12]
80–89.9% 0.8105 (0.2051) [12]
70–79.9% 0.7800 (0.2244) [12]
60–69.9% 0.7657 (0.2380) [12]
50–59.9% 0.7387 (0.2317) [12]
40–49.9% 0.6634 (0.2552) [12]
Mean value (SE) Source
Acute exacerbation-related disutility
Investigator-reported acute exacerbations: first month -0.140 (0.047) [12]
Investigator-reported acute exacerbations: subsequent months -0.078 (0.032) [12]
Adjudicated confirmed or suspected acute exacerbations: first month -0.274 (0.059) [12]
Adjudicated confirmed or suspected acute exacerbations: subsequent months -0.033 (0.053) [12]
Mean value Source
AE-related disutility
Serious cardiac events –0.0165 [32]
Serious gastrointestinal events –0.0057 [12]
Skin disordersa –0.0068 [32]
Gastrointestinal perforation –0.0098 [32]
Drug acquisition cost (per day) (£)
Nintedanib 71.70 [34]
Pirfenidone 71.70 [34]
N-Acetylcysteine 0.001125/mg [34]
BSC Assume zero (0) cost [12]
AE-related costs (per event) (£)
Serious cardiac events 2054.18 [35]
Serious gastrointestinal events 1749.45 [35]
Skin disorders 373.07 [35]
Gastrointestinal perforation 2352.99 [35]
Background follow-up costs by FVC %pred status (per cycle) (£)
C110% 219.19 [12]
100–109.9% 209.37 [12]
90–99.9% 236.57 [12]
80–89.9% 210.37 [12]
70–79.9% 253.49 [12]
60–69.9% 233.51 [12]
50–59.9% 312.53 [12]
40–49.9% 649.17 [12]
Acute exacerbation-related cost (per cycle) (£) 4133.59 [12]
Other costs (per cycle) (£)
Patient monitoring (liver panel tests) 3.01 [35]
Oxygen supplementation 417.93 [38]
Palliative care (EoL) 2560.84 [39]
AE adverse event, BSC best supportive care, EoL end of life, FVC %pred forced vital capacity percent predicted, N/A not applicable, SD standard
deviation, SE standard error
a Rash and photosensitivity reaction were grouped as ‘‘skin disorders’’
b As gastrointestinal perforation was a concern for nintedanib treatment, it was added to the analysis irrespective of severity/seriousness. Clinical advice at
the time indicated that it deserves a special mention as an event, as it may be very different to the gastrointestinal events already captured in the model
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synthesises quality-adjusted life-years (QALYs) and
healthcare costs. A comparison with triple therapy was not
considered, since after the recent results of PANTHER-IPF
[4] clinicians were urged to avoid it due to the excess
number of deaths, hospitalisations and serious AEs [40].
The base-case analysis was based on INPULSIS patient
characteristics (see Online Resource 1). The analysis was
conducted from a UK NHS and Personal Social Services
perspective. Costs and QALYs were discounted at the
standard annual rate of 3.5% [41] and half-cycle correction
was incorporated. Outcomes and transitions were estimated
over the cohort lifetime and were evaluated every
3 months, consistent with the duration between observa-
tions in the clinical trials used to estimate baseline transi-
tion probabilities [12].
We also conducted a subgroup analysis of a population
with an ‘‘increased risk of progression’’ as defined in the
ASCEND (Assessment of Pirfenidone to Confirm Efficacy
and Safety in Idiopathic Pulmonary Fibrosis) clinical trial
[29]. Here the survival analysis and individual patient data
analysis of the INPULSIS population were restricted to
mirror as much as possible the ASCEND selection criteria:
IPF diagnosed at least 0.5 years before visit 2, FVC
50–90% predicted, and forced expiratory volume in 1 s
(FEV1)/FVC C0.8. Table 5 reports the differences between
the base-case and the subgroup analysis.
Extensive one-way sensitivity analysis and probabilistic
sensitivity analysis (1000 samples) were performed.
Details on the PSA parameters and distributions are pre-
sented in Online Resource 6. External validation of the
model assumptions by leading UK clinical experts, and
internal validation of the OS, acute exacerbation and
FVC %pred distribution are presented in Online Resource
7.
Internal model verification was conducted by the model
developers. The same cost-effectiveness model was audited
by independent analysts during the NICE and SMC tech-
nology appraisals. Extreme value analyses were also
conducted to stress test the model results. The exe-
cutable file of the model was made available to the journal
for peer review.
3 Results
The base-case deterministic results showed that nintedanib
dominated pirfenidone, with lower costs and more QALYs
gained. This trend was attributed to the modelled acute
exacerbation events, which were fewer in patients treated
with nintedanib than in patients treated with pirfenidone.
The NMA results showed that the OR for acute exacer-
bations versus placebo was 0.56 (95% confidence interval
[CI] 0.35–0.89; statistically significant) for nintedanib and
1.10 (95% CI 0.43–2.85; not statistically significant) for
pirfenidone (Table 1).
Compared with BSC, the ICER for nintedanib and pir-
fenidone was over £100,000 per QALY gained (£145,310
per QALY gained for nintedanib and £172,198 per QALY
gained for pirfenidone), due to the high incremental cost
difference between the active treatments and BSC (ap-
proximately £60,000) (base year of currency values 2014)
(Table 6). N-Acetylcysteine was dominated by BSC, with
higher total costs and fewer QALYs gained; since it was an
inferior therapy; results are not shown for N-acetylcysteine.
For both nintedanib and pirfenidone, the increase in costs
was due to the drug acquisition costs. For nintedanib, drug
acquisition costs were 74% of the total value, while
background follow-up and oxygen use accounted for 13%
and EoL palliative care costs for 11% (Table 6; percent-
ages not shown). Due to their low frequency, acute exac-
erbations accounted for only 1% of the total costs. Finally,
AE-related and liver panel tests accounted for less than 1%
of the nintedanib costs. Note that these results are based on
the list prices of nintedanib and pirfenidone.
A series of sensitivity analyses (14 scenarios) were
performed on the range of 95% CIs of the main model
Table 5 Differences between the base-case and the subgroup analysis for the ASCEND population
Parameter Input
Patient distribution at the start of the model Subgroup of INPULSIS to match the ASCEND clinical trial [29] population characteristics
Overall survival, time to acute exacerbation,
lung function decline
A similar approach to the base-case analysis was followed, but for the ASCEND subgroup from
the nintedanib trials [11, 12]
An adjusted indirect treatment comparison was used for the relative effects of placebo
(reference) and pirfenidone
Treatment safety For comparability with the ASCEND trial [29], adverse events were compared with those from
the INPULSIS subgroup if they were observed with an incidence of C10%
Treatment tolerability Nintedanib overall discontinuation risk was calculated based on parametric modelling
extrapolation of phase III trial data from a subgroup of INPULSIS [12]
Pirfenidone discontinuation risk was based on the number of patients discontinuing treatment
throughout the ASCEND clinical trial [29]
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parameters; the results are shown as a tornado diagram for
nintedanib versus BSC (Fig. 3). Additional analyses (36
scenarios) were undertaken on model inputs to test model
assumptions and values used, as well as structural uncer-
tainty (see Online Resource 8). The analysis versus BSC
was sensitive to the mortality probabilities and assump-
tions. The nintedanib versus pirfenidone comparison was
sensitive to the acute exacerbation parameters; results
ranged from nintedanib being dominant (nintedanib cost
less and was more effective than pirfenidone) to having
ICER values of over £100,000 per QALY gained.
The result of the probabilistic sensitivity analysis (1000
samples) is presented in Fig. 4. The scatter plot indicates
that nintedanib and pirfenidone are broadly equivalent,
with samples for both treatments overlapping. The cost-
effectiveness acceptability curve is presented in Fig. 5 and
shows that nintedanib dominates pirfenidone at any
threshold level.
4 Discussion
The overall structure of the model used in this analysis has
similarities with the 2013 NICE clinical guideline model
comparing the cost effectiveness of a pulmonary rehabili-
tation course to a strategy offering no pulmonary rehabil-
itation in IPF patients [1]. Similar to the NICE model, our
analysis reflected disease progression as a change in
FVC %pred and also considered the impact of acute
exacerbations; one difference was the range of FVC %pred
category considered (1% in the NICE model vs. 10% in this
model).
In a different study, Loveman et al. [42] used IPF
‘‘unprogressed’’ and ‘‘progressed’’ (decline of 10% in
FVC %pred) health states. Although this approach sim-
plifies the disease progression model input, it assumed that
a Markov health state is defined by a change in the cohort
condition (a drop in FVC %pred). A change in condition is
Table 6 Incremental cost-effectiveness ratios for pirfenidone and nintedanib versus best supportive care
BSC (baseline) Pirfenidone Nintedanib
Total costs (£) 20,029.23 80,474.37 78,350.71
Drug acquisition costs 0.00 59,121.16 57,582.92
Treatment-related AE costs 589.13 1002.64 702.54
Patient monitoring (liver panel tests) costs 0.00 9.06 8.83
Background follow-up and oxygen use costs 9231.78 10,026.61 10,119.06
Acute exacerbation costs 1265.38 1486.63 1127.31
EoL palliative care costs 8942.94 8828.27 8810.06
Total QALYs 3.0999 3.4509 3.5013
ICER Baseline Dominated by nintedanib £145,310 per QALY gained vs. BSC
AE adverse event, BSC best supportive care, EoL end of life, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year
Fig. 3 Tornado diagram for
nintedanib vs. best supportive
care
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typically included in a Markov model as a health state
transition and not as a health state per se. The consequence
of using a change as a health state is that, depending on the
disease variation of the cohort at the start of the model, the
resulting Markov states are heterogeneous and not mutu-
ally exclusive. Nevertheless, despite the structural differ-
ences and distinct assumptions (e.g. the nintedanib price),
the results of the Loveman et al. [42] analysis are similar to
ours; nintedanib dominates pirfenidone in the deterministic
analysis, both treatments have ICERs over £100,000 per
QALY gained versus BSC, and treatment effect parameters
are the strongest drivers of the model results (in particular,
OS).
A recent economic evaluation, conducted alongside an
RCT, reported on the cost utility of antibiotic medicines in
IPF treatment in the UK [43]. The study used 12-month
data from the RCT [44] to produce costs and utility esti-
mates for co-trimoxazole and placebo. The study by Wil-
son et al. [43] estimated the 12-month costs for baseline
care (placebo) to be around £1500 per patient (excluding
prescription medicines). Our estimates were around
£1900–2000 per patient for routine monitoring and oxygen
use, management of AEs and acute exacerbations,
depending on whether it was active treatment or BSC. The
difference may be attributed to our resource use estimates,
being based on the results of a multi-country RCT com-
pared to a UK-only trial [43]. The difference may also be
random given the sample size in Wilson et al. [43] (65–70
patients) compared with the INPULSIS data (over 1000
patients) [12].
Fig. 4 Cost-effectiveness
scatter plot. BSC best supportive
care, PSA probabilistic
sensitivity analysis, QALYs
quality-adjusted life-years
Fig. 5 Multiple cost-
effectiveness acceptability
curve. BSC best supportive care
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We also note that the Wilson et al. [43] study found
increased QALY benefits for the co-trimoxazole strategy
compared with placebo (lowest incremental QALY esti-
mates of 0.032 increasing to 0.057). This is an important
difference to our findings in which our lifetime incremental
QALYs do not exceed the 0.5 mark; crudely, assuming a
5-year average survival for our cohort this means a 0.01
QALY gained per patient per 12 months. As in the case of
the cost estimates, the difference may be random, given the
small sample size of the study, or it could be attributed to a
small survival benefit observed in the co-trimoxazole
strategy.
Our economic analysis was based on evidence collected
from large international clinical trials and followed the
NICE reference case and international guidelines for best
practice in economic modelling [41, 45]. Its strengths
include the synthesis of EQ-5D and resource use data
obtained from the same source that provided the clinical
evidence for one of the comparators [12]. The clinical
inputs of the economic analysis were based on an NMA
conducted after a systematic review of the literature. The
NMA results were similar with three other studies
[42, 46, 47]. The OS parametric extrapolation estimates
used in the base-case analysis were validated with external
observational data [5, 19].
The model has several limitations. First, due to lack of
head-to-head data for nintedanib versus pirfenidone, sum-
mary statistics were used to calculate efficacy, safety and
tolerability for patients receiving pirfenidone. This intro-
duced practical difficulties in synthesising the evidence and
uncertainty around the relative efficacy and safety of the
two treatments, which needs to be considered when inter-
preting the evidence. Second, too few acute exacerbations
were recorded to allow statistically robust exploration of
their effect on mortality and disease progression. Conse-
quently, the impact of acute exacerbations may be under-
estimated. Third, since both nintedanib and pirfenidone are
new treatments for patients with IPF, there is a lack of
evidence on treatment tolerability and discontinuation in
real life. In our analysis, discontinuation rates were based
on those observed in clinical trials. This is likely to be
different from real-world observations. Nevertheless, the
model results were robust to changes in the assumptions on
treatment discontinuation. Fourth, the model assumed that
oxygen supplementation costs are incurred only by IPF
patients with an FVC %pred below 80%, which is likely to
overestimate the true cost associated with this resource.
However, the results were not sensitive in this cost
parameter.
Overall, N-acetylcysteine was found to have similar
costs to BSC and worse effectiveness, driven by the sur-
vival deficit in the NMA comparison. The nintedanib
strategy had fewer acute exacerbations and, consequently,
fewer costs and more QALYs than pirfenidone, but with
considerable uncertainty around the point estimates. In the
UK currently, a new healthcare intervention is considered
for reimbursement by the NHS if its ICER is below or
within £20,000–30,000 per QALY. Given the high incre-
mental cost difference between nintedanib and pirfenidone
versus BSC, the ICERs for both drugs were over £100,000
per QALY gained. This situation is frequently encountered
with drugs for rare medical conditions, and it has been
suggested that considerations of prevalence, budget impact,
disease severity and treatment options should be weighed
against cost-effectiveness parameters to arrive at a reim-
bursement price that is fair to both healthcare systems and
drug manufacturers [48–50].
NICE has recently published a decision on pirfenidone
and nintedanib for reimbursement in the NHS of England
and Wales [7, 8]. For both treatments, the committee
considered a confidential PAS, and approved them with
limited access based on two criteria: (a) initiation limited to
individuals with an absolute level of lung function—
FVC %pred between 50 and 80%; and (b) discontinuation
mandated for individuals exhibiting C10% annual decline
in FVC %pred. The origin for both these criteria appears to
be the appraisal of pirfenidone [8], during which NICE
concluded that pirfenidone offered an acceptable cost-ef-
fectiveness estimate in the subgroup of patients with an
FVC %pred of 80% or less, and that this was the most
appropriate population for evaluation. During that appraisal
NICE also heard from clinical specialists that there is a
‘‘consensus that a decline in FVC of 10% or more from a
baseline pre-treatment value represents progressive dis-
ease’’ [8]. Our estimates suggest that the cost-effectiveness
conclusion is not very different when considering a sub-
group of patients with ‘‘increased risk of progression’’,
when considering patients with 80% or lower FVC %pred
or when patients discontinue after progression.
Given the similar efficacy between nintedanib and pir-
fenidone, clinicians, policy makers and individuals with
IPF will need to consider drug costs, pill burden, and safety
and tolerability in making treatment choices [40]. Because
IPF occurs in an older population who are likely to have
co-morbid conditions, treatment administration (i.e. num-
ber of pills taken per day) and adverse effects related to
each drug may be important considerations for patient
satisfaction and treatment adherence. Ultimately, the
choice between nintedanib and pirfenidone may depend on
a wide range of factors such as patient lifestyle, co-mor-
bidities, ability to tolerate treatment [51], and even per-
sonal values, aversion to risk, willingness to take medicines
[52] and accuracy of information provided by the clinicians
[40].
Future clinical trials and long-term follow-up studies
should include survival and protection from acute
C. Rinciog et al.
exacerbations as outcomes, since they represent the ulti-
mate goal of therapy and are likely to have a large impact
on cost effectiveness. Prospective studies designed to
capture the real-world impact of treatment tolerability and
discontinuation are also needed, although our model was
not particularly sensitive to changes in discontinuation.
5 Conclusion
Compared with placebo, nintedanib was statistically better
in protection from acute exacerbations and delaying lung
function decline. In the same comparison, pirfenidone was
better than placebo in lung function decline. All com-
parators were estimated to have similar projected survival.
Based on these efficacy outcomes, over a patient’s lifetime,
nintedanib and pirfenidone accrued 0.5 QALYs more than
BSC (placebo). Given the high incremental cost difference
between nintedanib, pirfenidone and BSC, the ICER was
over £100,000 per QALY gained. Nintedanib and pir-
fenidone were largely equivalent in estimated costs and
health-related quality of life benefits in a pairwise com-
parison, and N-acetylcysteine was dominated by the ref-
erence treatment (BSC). The uncertainty around the results
was driven mainly by the lack of statistically significant
differences in the OS of the active treatments.
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